The best definitive treatment option for end-stage heart failure currently is transplantation,
which is limited by donor availability and immunorejection. Generating an autologous …

Cellular therapy using stem cells for cardiac diseases has recently gained much interest in
the scientific community due to its potential in regenerating damaged and even dead tissue …

Over 1000 patients have participated worldwide in clinical trials exploring the therapeutic
value of bone marrow-derived cells in ischemic heart disease. Meta-analysis evaluation of …

Embryonic stem cells have the distinct potential for tissue regeneration, including cardiac
repair. Their propensity for multilineage differentiation carries, however, the liability of …

Pluripotent stem cells demonstrate an inherent propensity for unrestricted multi-lineage
differentiation. Translation into regenerative applications requires identification and isolation …

Pathogenic causes underlying nonischemic cardiomyopathies are increasingly being
resolved, yet repair therapies for these commonly heritable forms of heart failure are lacking …

Myocardial infarction (MI) is a leading cause of hospitalization worldwide. A recently
developed strategy to improve the management of MI is based on the use of growth factors …

Nuclear transport of transcription factors is a critical step in stem cell commitment to a tissue-
specific lineage. While it is recognized that nuclear pores are gatekeepers of …

Clinical and basic scientific studies of stem cell-based therapies have shown promising
results for cardiovascular diseases. Despite a rapid transition from animal studies to clinical …

Background Adipose-derived stromal cells (ASCs) stimulated with vascular endothelial
growth factor (VEGF) and serum-deprived, are applied in the first in-man double-blind …